Biovaxys Technology Corp
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S)… Read more
Biovaxys Technology Corp (BVAXF) - Total Assets
Latest total assets as of April 2025: $1.10 Million USD
Based on the latest financial reports, Biovaxys Technology Corp (BVAXF) holds total assets worth $1.10 Million USD as of April 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biovaxys Technology Corp - Total Assets Trend (2018–2024)
This chart illustrates how Biovaxys Technology Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biovaxys Technology Corp - Asset Composition Analysis
Current Asset Composition (October 2024)
Biovaxys Technology Corp's total assets of $1.10 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Biovaxys Technology Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biovaxys Technology Corp's current assets represent 100.0% of total assets in 2024, an increase from 31.0% in 2018.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2024, up from 14.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biovaxys Technology Corp Competitors by Total Assets
Key competitors of Biovaxys Technology Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Biovaxys Technology Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biovaxys Technology Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biovaxys Technology Corp is currently not profitable relative to its asset base.
Biovaxys Technology Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.14 | 1.08 |
| Quick Ratio | 0.29 | 0.14 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.73 Million | $ -2.41 Million | $ 56.97K |
Biovaxys Technology Corp - Advanced Valuation Insights
This section examines the relationship between Biovaxys Technology Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.86 |
| Latest Market Cap to Assets Ratio | 0.78 |
| Asset Growth Rate (YoY) | 1046.3% |
| Total Assets | $1.30 Million |
| Market Capitalization | $1.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biovaxys Technology Corp's assets below their book value (0.78 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biovaxys Technology Corp's assets grew by 1046.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biovaxys Technology Corp (2018–2024)
The table below shows the annual total assets of Biovaxys Technology Corp from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-10-31 | $1.30 Million | +1046.27% |
| 2023-10-31 | $113.48K | -86.89% |
| 2022-10-31 | $865.56K | -89.82% |
| 2021-10-31 | $8.50 Million | -18.70% |
| 2020-10-31 | $10.46 Million | +3315.01% |
| 2019-10-31 | $306.26K | +181.64% |
| 2018-10-31 | $108.74K | -- |